Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Overview of attention for article published in Lancet Oncology, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 29 news outlets
blogs: 4 blogs
policy: 3 policy sources
twitter: 36 X users

patent: 22 patents
f1000: 1 research highlight platform
guideline: 10 clinical guideline sources

Readers on

mendeley: 1358 Mendeley

So far, Altmetric has seen 5 posts from 4 blogs.

IL-4: A Regulator of CART Cell Exhaustion

Springer Nature Sustainability Community, 22 Sep 2024

Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma

Physician's Weekly, 28 Feb 2022

1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene ciloleucel (axi-cel) showed…

CAR T-Cell Therapy an Unmitigated Success in Relapsed/Refractory DLBCL

Physician's Weekly, 22 Oct 2020

Management of the cytokine release syndrome seen in association with CAR T-cell therapy best done with early introduction of IL-6…

Linfoma: presentati i dati di efficacia e sicurezza dello studio registrativo ZUMA-1

Meteo Web, 03 Dec 2018

Presentati oggi nel corso del Congresso ASH (American Society of Hematology, abstract #2967) i dati di efficacia e sicurezza…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 1 additional blog posts.